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Abstract
Background: Since generic drugs have the same therapeutic effect as the original formulation but at generally
lower costs, their use should be more heavily promoted. However, a considerable number of barriers to their wider
use have been observed in many countries. The present study examines the influence of patients, physicians and
certain characteristics of the generics’ market on generic substitution in Switzerland.
Methods: We used reimbursement claims’ data submitted to a large health insurer by insured individuals living in
one of Switzerland’s three linguistic regions during 2003. All dispensed drugs studied here were substitutable. The
outcome (use of a generic or not) was modelled by logistic regression, adjusted for patients’ characteristics
(gender, age, treatment complexity, substitution groups) and with several variables describing reimbursement
incentives (deductible, co-payments) and the generics’ market (prices, packaging, co-branded original, number of
available generics, etc.).
Results: The overall generics’ substitution rate for 173,212 dispensed prescriptions was 31%, though this varied
considerably across cantons. Poor health status (older patients, complex treatments) was associated with lower
generic use. Higher rates were associated with higher out-of-pocket costs, greater price differences between the
original and the generic, and with the number of generics on the market, while reformulation and repackaging
were associated with lower rates. The substitution rate was 13% lower among hospital physicians. The adoption of
the prescribing practices of the canton with the highest substitution rate would increase substitution in other
cantons to as much as 26%.
Conclusions: Patient health status explained a part of the reluctance to substitute an original formulation by a
generic. Economic incentives were efficient, but with a moderate global effect. The huge interregional differences
indicated that prescribing behaviours and beliefs are probably the main determinant of generic substitution.
Background
Generic substitution has been associated with notable
monetary savings for society in several settings [1] and
represents one of several strategies aimed at curb phar-
maceutical expenditure [2-4]. Generic drugs, which con-
tain the same therapeutic substance as the original
formulation, become available once the patent protec-
tion granted to the brand name drug has expired, lead-
ing to greater market competition and lower prices [5].
To contain rising pharmaceutical costs, governments
and health insurers should do more to promote generic
substitution.
There are, however, different barriers to the wider use
of generic drugs. The first is the concern of patients.
About one third of patients expressed worries after gen-
eric substitution and some reported either a reduced
effect or new or increased side-effects [6,7]. Chronically
ill patients taking several drugs may feel unsettled [8],
particularly when different generics are offered each
time they buy their medication [9,10]. Such brand-to-
generic or generic-to-generic switches might be confus-
ing (patients taking the same substance but in a new
form), and problematic for certain medication classes
with a narrow therapeutic margin like anti-epileptics,
where seizures and other negative outcomes have been
reported [11,12]. Generic substitution could be an
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additional factor behind poor therapy adherence in
chronic diseases [10].
Furthermore, generic substitution is generally met
with skepticism by health professionals despite a lack of
proven differences in the clinical outcomes of generics
and original formulations [13,14]. Physicians who play a
central role in the prescription decision have their indi-
vidual prescribing habits [15] and tend to prescribe by
brand name, generally ignoring drug prices [16,17].
Pharmacies may also influence the choice of medication
by informing patients of the costs or by adopting proce-
dures that increase generic use.
Finally, economic and regulatory conditions play a
major role on the drugs market, with financial incentives
for all parties (prescribers, pharmacists, and patients)
being an important factor [2]. Patients who face higher
co-payments purchase more generics on average, and
they switch to a generic when the relative saving is high
[18]. Market characteristics, as well as pricing and licen-
sing policies also influence the use of generic drugs. The
market share of generics varies widely from one country
to another [19]. In markets where the generics’ share is
large, switching should be more commonplace. How-
ever, brand-name drugs tend to be heavily advertised
and prescribers tend to remain loyal to brands, allowing
them to keep their customers for long periods despite
being more expensive [14].
The aim of this study was to explore the relationship
between the use of generic drugs and its main determi-
nants, i.e. patients, physicians, and certain characteristics
of the generics’ market to adapt if necessary policies on
this area.
We used reimbursement claims data from a Swiss
health insurer for the year 2003. This period was chosen
specifically because it came two years after the introduc-
tion of new generic substitution rules in Switzerland
and preceded a reform imposing a minimum price dif-
ference between original formulations and generics. In
addition, drug prices were relatively stable during that
year. In the interests of identifying factors that could
lead to more efficient prescribing, three cantons were
selected, one from each linguistic region of Switzerland.
Methods
Setting
Until 2005 Switzerland had the second smallest market
share of generic drugs in Europe and, until recently, the
generic substitution rate was well below the average
[20]. Two thirds of drugs were reimbursed by the com-
pulsory health insurance system, and accounted for
more than 20% of health insurers’ expenditures.
It is compulsory for all Swiss residents to purchase a
health insurance contract. All health insurance funds
offer the same package, as set down by the federal
authorities, which features a list of reimbursable pre-
scription drugs. Swiss patients contribute to the cost of
care through the payment of an annual deductible. They
are free to choose the level of their deductible, but the
higher the deductible the lower the premium they pay.
In 2003, there was no mandatory deductible for children
under 18, and a minimum deductible of 230 Swiss
francs for adults. The highest was 375 Swiss francs for
children and 1,500 Swiss francs for adults. Furthermore,
once this is reached, the insured is subject to a co-
payment of 10% of the cost of any care service he has
received. Co-payments are capped at an annual ceiling
depending on the deductible (300 to 2,100 Swiss francs).
This means that insurance contracts only differ in terms
of the financial incentives associated with the deductible
levels, and not in the types of care or drugs that are
covered. All patients therefore face the same choice of
branded or generic drugs for a given indication.
Recent generic medicine policy implemented in
Switzerland
Since January 2001, pharmacists have been authorized to
substitute original drugs with generics provided that
they have the agreement of the patient and have
informed the prescribing physician. Since July of the
same year pharmacists have received a fixed fee when
dispensing a generic drug, independent of the price of
the dispensed drug, which avoids financial penalization.
There is no reference pricing scheme that requires the
patient to pay the difference between the actual price of
the medicine and the reference price. However, since
2006, patient copayments for brand drugs have been
raised from 10% to 20%. To be admitted to the reim-
bursed drugs list, generics need to be priced lower than
the branded drug. This means a minimal saving in com-
parison with the originator being requested since 2005
(in 2009, -20% to -50%, depending on market size).
Switzerland has no other mechanisms in place like man-
datory guidelines and expenditure targets to regulate
physicians’ generic prescription practices.
Studied population
The data used in this study were on the drugs’ reimbur-
sement claims submitted by the entire population of
insured of one of Switzerland’s largest health insurers
(CSS), who lived in one of three cantons - Aargau,
Ticino and Vaud - during 2003. In Switzerland, most
drugs are delivered through medical prescriptions, but
some over-the-counter (OTC) drugs are also reimbursed
if prescribed by a physician.
This source population of 169,837 subjects repre-
sented 15.6%, 10.4%, 7.6% of the population of these
cantons respectively. Each canton reflects one of
Switzerland’s three main linguistic regions (German-
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speaking Aargau, French-speaking Vaud and Italian-
speaking Ticino), and none allows physicians to dispense
drugs [21]. Those insured with CSS were slightly older
than the general Swiss population (14% of insured were
70 years old or more, against 11% in the general popula-
tion during the same year) but their gender distribution
was similar. Nevertheless, the odds ratios were adjusted
for age and gender, allowing a generalization of the
observed associations to broader populations. Indeed, it
was highly improbable that there was any association
between the studied effects and characteristics of the
sample populations. In particular, there is no evidence
that those insured with the CSS had different incentives
than others, because in 2003 HMOs and managed care
services were scarce in Switzerland and also in the three
cantons.
The studied population consisted of all observations
relating to substitutable drugs. To be considered substi-
tutable, a drug must have had at least one generic and
one brand-name counterpart sold in Switzerland and
was reimbursable by the compulsory basic health insur-
ance system in 2003. Counterpart here means the same
active substance, pharmaceutical form (tablets, drops,
etc.), dosage, administration route (oral, inhalation, etc.),
similar packaging size (differences in number of doses
lower than 30%) and intended use as defined in the
Swiss Medicines Compendium [22]. Each substitutable
drug was thus allocated to a substitution group which
was identified by the branded original and comprised all
its corresponding generic products. Our dataset com-
prised a total of 298 substitution groups, generics corre-
sponding to 20.4% of the total quantity of drugs
delivered in 2003. The observation unit was one drug
prescribed to an insured patient by a physician and dis-
pensed by a pharmacist. A renewable prescription (same
drug prescribed by the same physician) was counted
only once if it was dispensed by the same pharmacist, as
it was considered to be the consequence of the same
decision. To avoid the inclusion of exceptional prescrib-
ing situations, we only considered drugs that were pre-
scribed by a physician and dispensed by a pharmacist to
a patient resident in the same canton.
Outcome
The study outcome was to ascertain whether the patient
had received a generic drug or not.
Predictors of generic drug use
Theoretically, there are at least three main promoting
(+) or hindering (-) determinants of the use of generics:
patients, physicians and the drugs’ market, (Figure 1).
As mentioned in the background section, patients with
poor health status (the old, complex treatments) tend to
be reluctant to use generic drugs. However, in a co-
payment setting (high deductible and out-of-pocket par-
ticipation), patients tend to prefer saving money, and
are likely to choose a generic over a branded drug, espe-
cially if the price of the latter is much higher than that
of the former. Patients were characterized by demo-
graphic variables (gender and age categories: 0-19, 20-
39, 40-59, 60-79, and 80+), by treatment complexity
which was represented by the number (1-5, 6-10, 11-15,
16-20, 21+) of the 4th level (chemical subgroups) of
Anatomical Therapeutic Chemical (ATC) codes of dis-
pensed drugs (chemical subgroup level), by whether
they had chosen an optional health insurance deductible
over the standard minimum deductible, by out-of-
pocket participation (more precisely by whether the
financial participation of the patient remained under the
maximum participation amount, comprising the deduc-
tible and co-payments), and by the canton of residence
(Aargau, Ticino or Vaud). Treatment complexity can be
measured by the ATC drug classification system because
dispensed drugs are a direct measure of treated morbid-
ity and have already been used as a risk adjustment tool,
particularly when diagnostic information is not available
[23]. A simple count of dispensed drugs in the current
year would overestimate the disease burden. Several
similar active ingredients (i.e. two anti-hypertensives in
the same therapeutic class) reflect rather different effects
(adverse events or efficacy) other than the disease sever-
ity. Several drugs in different therapeutic chemical sub-
groups, such as antihypertensives with different
mechanisms of action, reflect a more serious condition.
Given that physicians write prescriptions, they heavily
influence the choice of medication. Since our study
focused on three cantons which did not have significant
drug dispensation by physicians, the latter had no finan-
cial interest in the choice of drugs and were assumed to
be “loyal agents” acting in the interests of their patients.
It was therefore difficult to formulate a priori hypoth-
eses about their influence. Prescribing physicians’ vari-
ables were their practice status (hired by a hospital,
independent specialist, independent general physician or
internist), and the canton where they worked.
The only information on pharmacies was the canton
where they were located. This lack of information
should not compromise the study, because Swiss phar-
macists had no significant financial disincentives to dis-
pense generics. Since we excluded out-of-canton drug
dispensation, the canton variable was the same for
patients, physicians and pharmacies, and was thus
included as a separate category and only once.
There is no evidence to support the assumption that
the size of the generic market has a bearing on generics’
substitution. On the contrary, launching new galenic
and packaging forms were found to be effective mechan-
isms for maintaining consumption of brand name drugs.
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The substitution groups were characterized by
the number of different generic drugs available in
Switzerland in 2003 (1-2, 3-4, 5-6, and 7+), the number
of patients treated (1-1000, 1001-2000, 2001-3000, and
3,000+), the unit price of the original (expressed in
quintiles), the relative price difference (the price of the
original per unit minus the price of the cheapest drug in
the group divided by the price of the original, expressed
in quintiles), the administration mode (oral, topical,
nasal, inhalation or ophthalmic preparations; others),
whether there were multiple packaging sizes, whether
there was an additional galenic form for a branded drug
(for example effervescent, sublingual or extended release
medication), whether the group had at least one co-
branded original (product sold under license or a copy
of the original with different packaging, such as blister
pack, box or bottle). Repackaging and reformulating a
brand-name drug is a common technique used to main-
tain the attractiveness of the originals product. To avoid
a collinear association with the price of the medication,
we used the number of patients treated in each substitu-
tion group rather than the total amount of sales as an
indicator of the size of the market.
Finally, we introduced the 298 substitution groups as
dummy variables to identify the possible influence of
other aspects of the treatments.
Statistical model
The aim of the analysis was to separate the factors
related to the dispensing procedure (such as patient or
physician characteristics) from the characteristics of the
substitution groups depicting the drugs market. We
used three logistic models. The simpler model (Model
A) comprised only the patient and physician variables
and the cantons. However, we did include some first-
order interactions between the variables.
We then added dummy indicators of the substitution
groups, which take the value 1 if the observation (the
drug) belongs to the substitution group and 0 if not
(Model B). Finally, the third model (Model C) includes
all the variables of Model A and all the variables
describing the substitution groups.
The area under the receiver operating characteristic
(ROC) curve (C-statistics) was used to assess the discri-
minatory power of the predictive model and the Hos-
mer-Lemeshow table to test its calibration. Akaike’s
information criterion (AIC) and Schwarz’s Bayesian
information criterion (BIC) were used to compare the
competing models [24].
To estimate how different policies could influence
generic drug use, we computed the marginal effects of
all the variables from Model C (the most complete
model). They were computed as discrete differences
from the reference category (zero for binary variables,
and as mentioned in the table for categorical variables).
For example, the marginal effect of the variable is the
difference between the probability of generic drug use
when everyone is considered to be between 0 and
19 years old, and the probability when everyone is con-
sidered as to be between 60 and 79 years old, while all
Poor health status Economic incentives
(age, complexity of treatment) (deductible, out of pocket)
Physicians
Generic Regions (cantons)
use Practice (GPs, hospital, specialists)
Size of the market Diversification Nature of the treatment
number of generics and patients (packaging, galenic, etc.) 298 substitution groups
Patients
Pharmaceutical market
-
+
+
-
+-
+-
Figure 1 Conceptual framework and assumed determinants of generic use.
Decollogny et al. BMC Health Services Research 2011, 11:17
http://www.biomedcentral.com/1472-6963/11/17
Page 4 of 12
other variables hold constant. The computation was not
possible for the administration mode and the three
character ATC code due to missing cells, caused by the
fact that not all administration modes are compatible
with all ATC codes.
All statistical analyses were performed using Stata 11.0
(Stata Corp LP, College Station, Texas, USA).
Results
The source population included 1,341,197 drug dispen-
sations, among which 273,797 were eligible for generic
prescription. This population fell to 186,569 after aggre-
gating multiple deliveries and to 173,212 once out-of-
canton prescriptions (physicians, pharmacist or patients
from a different canton) were excluded.
Univariate analysis
Descriptive statistics and the results of the univariate
analysis (logit model with only one variable and a con-
stant as explanatory variables) are given in Table 1. The
overall substitution rate of generics was 31%, with con-
siderable differences across the three cantons (Aargau:
43%, Ticino: 12%, Vaud: 35%). Low substitution rates
(odds ratios significantly < 1) were associated with
female and older patients, optional health insurance
deductibles, treatment complexity (more than 10 differ-
ent drugs delivered in the same year), hospital prescri-
bers, cheaper brand medication, non-oral administration
modes, a substitution group consisting of an original
with a special galenic form or involving at least one pro-
duct sold under license. Higher rates were observed
among young patients, those subject to out-of-pocket
participation, substitution groups containing many gen-
erics or many patients, large relative differences in price
or varying packaging sizes.
Multivariate analysis
The results of the multivariate analysis are given in
Table 2.
A multivariate logistic regression with only the
patients’ variables and cantons gave results similar to
the univariate analysis, except for the “deductible” vari-
able (Table 2, Model A). Higher deductibles were asso-
ciated with lower generic substitution in the univariate
analysis but higher rates in the multivariate analysis.
One explanation for this finding was confounding by
age. The youngest had the highest substitution rates
regardless of their deductible and more frequently had a
standard deductible (>90%) than adults (<60%). Other
factors such as treatment complexity might influence
both the choice of deductible and the substitution beha-
vior. Among the oldest age group, out-of-pocket partici-
pation favored generic use much less. Cantons exerted
the strongest influence on substitution rates. The
influence of age on substitution rates also differed across
cantons. In the canton of Vaud, substitution rates
tended to be higher for the youngest and lower for the
oldest. The inverse correlation between age and substi-
tution rates was less pronounced in Ticino, where rates
were uniformly low. Generic use among hospital physi-
cians was particularly low in Ticino. In both Ticino and
Vaud, out-of-pocket participation had a lower incentive
effect on substitution.
Model A passed the Hosmer and Lemeshow [25]
goodness of fit test, with a p-value of 0.83.
Taking the heterogeneity of the substitution groups
into account did not change the observed trends signifi-
cantly, but improved the discriminatory power of the
model. The C-statistics moved from less than 70% to
over 81% (Table 2, Model B), thus providing evidence
that the characteristics of a given generic drug have a
significant bearing on the substitution rate.
The replacement of substitution groups by all their
measurable characteristics provide a model of compar-
able predictive performance with a 79% C-statistics
(Table 2, model C). Substitution rates for non-oral for-
mulations were always significantly lower than pills (all
coefficients significantly < 0). Market-related variables
had a considerable effect on substitution rates. The
number of patients treated, the number of generics
offered on the market, and the relative savings with the
substitutable product increased substitution rates. Dupli-
cates of original drugs (galenic form and drugs sold
under license and multiple package sizes) acted as bar-
riers to substitution.
The Hosmer and Lemeshow tests for Models B and C
indicated a lack of fit. This was due mainly to missing
interaction effects between the cantons and the group
identifiers in Model B and the market variables in
Model C. We excluded these effects in order to keep
the models tractable. Moreover, for very large samples
like ours, the Hosmer-Lemeshow test is often oversensi-
tive to detect lack of fit [26].
The marginal effects of each factor are reported in
Table 3. The negative impact of health status was rather
weak: the combined effect of old age and treatment
complexity did not exceed a 3% difference in substitu-
tion rates. Although the deductible amount and cost
participation were associated with an increased use of
generics, their effects were moderate: less than 1% for a
non-standard deductible and 2% for patients who did
not reach their maximum out-of-pocket participation. In
contrast, generic market share strongly influenced gen-
eric use. Introducing new generics on the market would
increase the substitution rate from 8 to 12%. One thou-
sand patients more increased use from about 2% to 7%
till 3,000 patients. Each additional quintile of relative
price savings contributes on average an additional 1.5%
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Table 1 Descriptive statistics and univariate logit estimates
Frequency Substitution rate Odds ratio 95%CI
OUTCOME VARIABLE Use of a generic drug (yes = 1, no = 0) 0.313
CANTONS
Aargau (reference) 0.372 0.433
Vaud 0.329 0.350 0.706 [0.689, 0.722]
Ticino 0.299 0.124 0.186 [0.181, 0.192]
PATIENTS’ VARIABLES Female:
no (reference) 0.378 0.317
yes 0.622 0.311 0.972 [0.952, 0.993]
Age:
0-19 0.100 0.411 2.057 [1.986, 2.131]
20-39 0.158 0.410 2.050 [1.989, 2.112]
40-59 0.250 0.344 1.543 [1.502, 1.585]
60-79 (reference) 0.356 0.254
80+ 0.136 0.228 0.868 [0.838, 0.900]
Optional health insurance deductible:
no (reference) 0.619 0.344
yes 0.381 0.264 0.685 [0.671,. 0.700]
Out-of-pocket participation:
no (reference) 0.396 0.241
yes 0.604 0.361 1.777 [1.740, 1.816]
Treatment complexity:
1-5 drugs 0.215 0.424 1.429 [1.390, 1.469]
6-10 drugs (reference) 0.290 0.340
11-15 drugs 0.223 0.280 0.757 [0.735, 0.779]
16-20 drugs 0.139 0.246 0.634 [0.613, 0.657]
21+ drugs 0.133 0.202 0.491 [0.473, 0.509]
PHYSICIANS’ VARIABLES Specialist prescriber:
no (reference) 0.777 0.314
yes 0.223 0.310 0.978 [0.955, 1.003]
Hospital prescriber:
no (reference) 0.880 0.325
yes 0.120 0.225 0.603 [0.583,.0.624]
SUBSTITUTION GROUPS’ VARIABLES Number of generics
1-2 (reference) 0.333 0.153
3-4 0.260 0.374 3.322 [3.225, 3.422]
5-6 0.298 0.415 3.934 [3.823, 4.049]
7+ 0.110 0.382 3.430 [3.305, 3.559]
Number of treated patients:
1-1000 (reference) 0.361 0.263
1001-2000 0.259 0.322 1.334 [1.299, 1.370]
2001-3000 0.122 0.223 0.803 [0.774, 0.834]
3001+ 0.257 0.418 2.017 [1.965, 2.070]
Price of brand medication:
1st quintile 0.189 0.327 1.000 [0.969, 1.031]
2nd quintile 0.165 0.251 0.689 [0.666, 0.713]
3rd quintile (reference) 0.239 0.327
4th quintile 0.187 0.328 1.002 [0.972, 1.034]
5th quintile 0.220 0.321 0.972 [0.943,.1.001]
Relative price difference:
1st quintile 0.188 0.200 0.599 [0.578, 0.620]
2nd quintile 0.200 0.347 1.267 [1.227, 1.308]
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substitution. However, the diversification of brand drug
supply through minor modifications had a strong nega-
tive effect on generic use (galenic form -7%, additional
patent -5%, multiple packaging size -4%).
Prescribing practices, which were measured across
hospital physicians, specialist physicians and cantons,
had the strongest impact on generic substitution. The
substitution rate in the canton of Ticino was much
lower (-26%) than in Aargau. The rate difference
between hospital physicians and specialists was -13%
and -3% between hospital and general physicians.
Among substitutable drugs, only one was included in
the list of narrow therapeutic index published by the US
Food and Drug Administration [27]: carbamezepine,
which was at the 13th percentile of substitution odds
(rather low).
Discussion
According to our data, generics’ prescriptions in 2003
accounted for only 20% of the overall prescription
volume. In contrast, generics accounted for more than
40-60% in some OECD countries [5], even though the
generics markets are not totally comparable. It is there-
fore possible that our results could not be replicated
exactly in other countries due to differences in the nat-
ure of the generics’ market.
We found that the variations in substitution rates
across the cantons were similar to those observed across
European countries (36% in Germany, 8% in France and
4% in Spain, for instance) during the same period.
Adjusting for potential disparities in health status, pre-
scriptions or prescribers’ characteristics did not alter
these variations, which suggests that the impact of
cultural aspects such as prescribing behaviours or beliefs
about generic substitution may be as important as
national policies. This interpretation is confirmed by the
finding that hospital physicians substituted less, and
should therefore be a focus of any future initiatives
encouraging more effective outpatient prescribing
practices.
As shown in previous studies, poorer health status,
captured in the present study by age and treatment
complexity, was associated with lower generic use.
Older people are less willing to substitute when offered
the choice [28]. This result is congruent with another
study on hypertensive patients, which found that substi-
tution had generated poor adherence, as well as worries
and confusion regarding the new treatment, especially
when more than one equivalent generic drug was used
[10]. For instance, a clear and conspicuous indication of
the prescribed substance that is the same for both the
branded and the generic drug could improve patient
confidence.
Pricing and reimbursement regulations thus appear to
be of utmost importance when it comes to increasing
generic use. Consumers facing high out-of-pocket costs
bought more generics. They were more likely to substi-
tute generics when the savings relative to brand name
price would be high. However, the marginal effects of
financial incentives related to insurance coverage were
rather weak in our study. This could be explained by
the annual ceiling of patients’ co-payments that protect
people against high out-of-pocket expenses. Another
reason could be the relatively low proportion of phar-
maceutical costs in Switzerland (less than 10% of total
out-of pocket health expenditures against 19 to 65% in
Table 1 Descriptive statistics and univariate logit estimates (Continued)
3rd quintile (reference) 0.206 0.295
4th quintile 0.204 0.301 1.029 [0.996, 1.062]
5th quintile 0.203 0.416 1.701 [1.649, 1.754]
Administration mode:
Oral (reference) 0.839 0.328
Topic 0.095 0.285 0.817 [0.788, 0.847]
Inhalation, nasal & ophthalmic 0.032 0.046 0.099 [0.087, 0.112]
Parenteral, rectal & vaginal 0.034 0.273 0.769 [0.726, 0.815]
Original with special galenic form:
no (reference) 0.862 0.338
yes 0.138 0.160 0.373 [0.359, 0.386]
At least one drug sold under license:
no (reference) 0.818 0.316
yes 0.182 0.300 0.929 [0.904, 0.954]
Multiple package sizes:
no (reference) 0.575 0.294
yes 0.425 0.339 1.232 [1.207, 1.258]
Observations 173,212
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Table 2 Determinants of generics use (logistic regression)
Model A Cantons and
patients variables
Model B Model A + substitution
groups dummies
Model C Model A + substitution
groups variables
Coeff. [95%CI] Coeff. [95%CI] Coeff. [95%CI]
CANTON:
Aargau (reference)
Vaud -0.253 [-0.31,-0.20] -0.247 [-0.31,-0.19] -0.248 [-0.31,-0.19]
Ticino -1.391 [-1.46,-1.32] -1.459 [-1.53,-1.39] -1.463 [-1.53,-1.39]
PATIENTS’ VARIABLES Female 0.023 [0.00,0.05] 0.031 [0.01,0.06] 0.017 [-0.01,0.04]
Age:
0-19 0.340 [0.24,0.44] 0.238 [0.12,0.36] 0.207 [0.09,0.32]
20-39 0.291 [0.22,0.36] 0.101 [0.02,0.18] 0.127 [0.05,0.21]
40-59 0.237 [0.18,0.30] 0.158 [0.09,0.22] 0.164 [0.10,0.23]
60-79 (reference)
80+ -0.135 [-0.21,-0.06] -0.018 [-0.10,0.06] -0.041 [-0.12,0.04]
Age 0-19 in Vaud 0.199 [0.12,0.28] -0.004 [-0.10,0.09] 0.086 [-0.00,0.18]
Age 20-39 in Vaud 0.026 [-0.05,0.10] 0.055 [-0.02,0.14] 0.051 [-0.03,0.13]
Age 40-59 in Vaud -0.058 [-0.12,0.01] -0.051 [-0.12,0.02] -0.046 [-0.11,0.02]
Age 80+ in Vaud 0.185 [0.10,0.27] 0.194 [0.10,0.29] 0.211 [0.12,0.30]
Age 0-19 in Ticino -0.437 [-0.58,-0.30] -0.548 [-0.70,-0.40] -0.484 [-0.63,-0.34]
Age 20-39 in Ticino -0.160 [-0.26,-0.06] -0.176 [-0.28,-0.07] -0.168 [-0.27,-0.07]
Age 40-59 in Ticino -0.208 [-0.29,-0.13] -0.192 [-0.28,-0.11] -0.189 [-0.27,-0.10]
Age 80+ in Ticino 0.095 [-0.01,0.20] 0.075 [-0.03,0.18] 0.098 [-0.01,0.20]
Optional health insurance deductible 0.065 [0.04,0.09] 0.039 [0.01,0.07] 0.043 [0.02,0.07]
Out-of-pocket participation 0.233 [0.18,0.28] 0.146 [0.09,0.20] 0.178 [0.12,0.23]
Out-of-pocket participation at age 0-19 0.084 [-0.02,0.19] 0.069 [-0.04,0.18] 0.043 [-0.07,0.15]
Out-of-pocket participation at age 20-
39
0.205 [0.13,0.28] 0.165 [0.08,0.25] 0.139 [0.06,0.22]
Out-of-pocket participation at age 40-
59
0.052 [-0.01,0.11] -0.020 [-0.09,0.05] -0.025 [-0.09,0.04]
Out-of-pocket participation at age 80+ -0.161 [-0.24,-0.09] -0.150 [-0.23,-0.07] -0.136 [-0.22,-0.05]
Out-of-pocket participation in Vaud -0.062 [-0.12,-0.01] -0.066 [-0.12,-0.01] -0.067 [-0.12,-0.01]
Out-of-pocket participation in Ticino -0.107 [-0.18,-0.04] -0.097 [-0.17,-0.02] -0.116 [-0.19,-0.04]
Treatment complexity:
1-5 drugs 0.112 [0.08,0.14] 0.096 [0.06,0.13] 0.082 [0.05,0.11]
6-10 drugs (reference)
11-15 drugs -0.063 [-0.09,-0.03] -0.055 [-0.09,-0.02] -0.055 [-0.09,-0.02]
16-20 drugs -0.089 [-0.13,-0.05] -0.101 [-0.14,-0.06] -0.102 [-0.14,-0.06]
21+ drugs -0.186 [-0.23,-0.14] -0.175 [-0.22,-0.13] -0.174 [-0.22,-0.13]
PHYSICIANS’ VARIABLES Specialist
prescriber
-0.245 [-0.27,-0.22] -0.203 [-0.23,-0.17] -0.194 [-0.22,-0.16]
Hospital prescriber in Aargau -0.871 [-0.93,-0.81] -1.125 [-1.19,-1.06] -1.101 [-1.17,-1.04]
Hospital prescriber in Vaud -0.344 [-0.40,-0.29] -0.559 [-0.62,-0.50] -0.571 [-0.63,-0.51]
Hospital prescriber in Ticino -0.737 [-0.84,-0.63] -0.778 [-0.89,-0.67] -0.756 [-0.86,-0.65]
SUBSTITUTION GROUPS’ VARIABLES
Number of generics:
1-2 (reference)
3-4 0.506 [0.46,0.55]
5-6 0.745 [0.70,0.79]
7+ 0.522 [0.46,0.58]
Number of treated patients:
1-1000 (reference)
1001-2000 0.109 [0.07,0.15]
2001-3000 0.412 [0.35,0.47]
3001+ 0.013 [-0.03,0.06]
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12 OECD countries [20] when OTC products are
included). In 2006, the co-insurance rate increased to
20% instead 10% for brand-name drugs for which less
expensive interchangeable generics are available. Mini-
mum costs savings rate per product were also intro-
duced to boost generic use. It would be interesting to
assess the impact of these two changes on the propen-
sity towards generic use.
The analysis of the substitution market generated
interesting additional observations.
First, we found that more generics’ competitors, a
large market and more potential cost savings for consu-
mers increased generic use. In Switzerland, administra-
tive constraints (such as the translation of labels in the
three official languages), high patent protection and the
small market size may thus explain the low generic mar-
ket share.
Second, measures to protect brand name exclusivity
such as reformulations and repackaging were also effec-
tive in curbing generic distribution. Although these
minor changes may confer benefits on some patients, it is
also possible that others may be switched inappropriately
to these reformulated drugs, whose prices are higher
than the generics. For instance, a recent meta-analysis on
cardiovascular drugs found no evidence to support the
claim that these peripheral differences between brand
name and generic drugs (such as inert binders, fillers, or
specific manufacturing processes) constitute a significant
clinical advantage [29].
Our study has limitations. The source population was
limited to a single, large insurance company and it is
therefore possible that the population was not totally
representative of the Swiss population. Another issue is
related to the non-reimbursement of dispensed drugs
for patients who have not asked for reimbursement. The
actual substitution rate on the Swiss generics market
therefore could be slightly higher than observed.
Furthermore, our results could not reflect the behaviour
of patients in relatively good health who did not reach
the deductible. After adjustment of measurable factors,
there remained large differences in mean substitution
rates among patients, physicians and pharmacies.
Further qualitative research would be useful to identify
modifiable behavioral determinants.
Table 2 Determinants of generics use (logistic regression) (Continued)
Price of brand medication:
1st quintile 0.181 [0.13,0.23]
2nd quintile -0.006 [-0.07,0.05]
3rd quintile (reference)
4th quintile 0.072 [0.03,0.12]
5th quintile -0.064 [-0.12,-0.01]
Relative price difference:
1st quintile -0.303 [-0.35,-0.25]
2nd quintile -0.167 [-0.21,-0.12]
3rd quintile (reference)
4th quintile 0.026 [-0.02,0.07]
5th quintile 0.219 [0.16,0.28]
Administration mode: Oral (reference)
Topic -0.644 [-0.71,-0.57]
Inhalation, nasal & ophthalmic -1.329 [-2.05,-0.61]
Parenteral, rectal & vaginal -0.676 [-0.76,-0.59]
Original with special galenic form -0.476 [-0.55,-0.41]
At least one drug sold under license -0.309 [-0.36,-0.26]
Multiple package sizes -0.233 [-0.27,-0.19]
Constant -0.554 [-0.60,-0.50] 0.717 [0.64,0.80] -0.289 [-0.38,-0.20]
Substitution groups dummies No Yes No
3 char. ATC codes dummies No No Yes
Pseudo-R-squared 0.089 0.229 0.194
AIC 196,349 166,597 173,677
BIC 196,671 169,867 174,542
Area under ROC curve 0.699 0.811 0.791
Hosmer-Lemeshow chi2 4.295 101.676 139.595
Prob > chi2 0.830 0.000 0.000
Observations 173,212 173,212 173,212
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Table 3 Average marginal effects (logistic regression - Model C)
Marginal effect 95%CI
CANTON
Aargau (reference)
Vaud -0.040 [-0.045 -0.034]
Ticino -0.260 [-0.265 -0.255]
PATIENTS’ VARIABLES Female 0.003 [-0.001 0.007]
Age:
0-19 0.031 [0.022 0.040]
20-39 0.035 [0.028 0.041]
40-59 0.016 [0.011 0.022]
60-79 (reference)
80+ -0.005 [-0.013 0.002]
Optional health insurance deductible 0.007 [0.003 0.012]
Out-of-pocket participation 0.023 [0.018 0.028]
Treatment complexity:
1-5 drugs 0.014 [0.009 0.020]
6-10 drugs (reference)
11-15 drugs -0.009 [-0.015 -0.004]
16-20 drugs -0.017 [-0.024 -0.010]
21+ drugs -0.029 [-0.037 -0.021]
PHYSICIANS’ VARIABLES Specialist prescriber -0.032 [-0.037 -0.027]
Hospital prescriber -0.131 [-0.137 -0.125]
SUBSTITUTION GROUPS’ VARIABLES Number of generics:
1-2 (reference)
3-4 0.083 [0.075 0.090]
5-6 0.125 [0.118 0.133]
7+ 0.085 [0.076 0.095]
Number of treated patients:
1-1000 (reference)
1001-2000 0.018 [0.012 0.025]
2001-3000 0.071 [0.060 0.082]
3001+ 0.002 [-0.006 0.010]
Price of brand medication:
1st quintile 0.031 [0.023 0.039]
2nd quintile -0.001 [-0.011 0.009]
3rd quintile (reference)
4th quintile 0.012 [0.004 0.020]
5th quintile -0.011 [-0.019 -0.002]
Relative price difference:
1st quintile -0.050 [-0.058 -0.042]
2nd quintile -0.028 [-0.036 -0.020]
3rd quintile (reference)
4th quintile 0.004 [-0.004 0.013]
5th quintile 0.038 [0.028 0.048]
Original with special galenic form -0.077 [-0.088 -0.066]
At least one drug sold under license -0.051 [-0.058 -0.043]
Multiple package sizes -0.039 [-0.045 -0.032]
Notes:
* p < 0.05 ** p < 0.01 *** p < 0.001.
The marginal effect for discrete and factor variables is the discrete change from the reference level.
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Nevertheless, our findings highlight that policies on
pricing and reimbursement are important as an impetus
for the generic medicines market but not sufficient for a
sustained generic market share. The opposite effects of
stimulating the substitution market or protecting brand
products provide some evidence that generic substitu-
tion is more than a simple question of time.
The policy measures recently introduced in Switzerland
- 20% co-payment for brand drugs, minimal savings
between originals and generics - should be effective since
the relative price difference and out-of-pocket participa-
tion variables were both significantly associated with a
higher rate of generic use. However, if all existing incen-
tives under the control of health policies were fully
applied, i.e. maximizing patients’ contribution to the
costs of care through deductibles and out-of-pocket
payments and increasing the number of generics on the
market, they would provide an additional potential switch
towards generics of about 10% (see Table 3: patient con-
tribution +3.0%, switching from 1-2 generics to 3-4 +
8.3%). Additional pricing and reimbursement rules
should be introduced in Switzerland to boost generic
drug substitution to the levels observed in other OECD
countries. In particular, the introduction of a nationwide
reference pricing scheme should be discussed. Wide dif-
ferences betweens counties suggest that educational
approaches targeted at physicians should be investigated
with a view to increasing their confidence in generics’
efficacy and safety.
The relatively low substitution rate observed for carba-
mazepine could be explained by the reluctance of physi-
cians to prescribe drugs classified in the list of
substances with narrow therapeutic margins.
Conclusion
The determinants of generic substitution are numerous.
Patients’ health status (age and complexity of treatment)
explain a part of the reluctance to substitute an original
formulation by a generic, but this uncontrollable deter-
minant is responsible for only a tiny part of substitution
rate variations. The economic incentives (deductible and
out-of-pocket participation of patients, number of gener-
ics sold on the Swiss market) were efficient, but with a
moderate global effect. In contrast, adopting the practices
of the canton with the highest generic use would itself
increase the substitution rate from up to 26%. There was
also evidence that an abundant supply of generics would
also provide strong incentives to shift towards generics.
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